In Brief: CBER clinical holds
Executive Summary
CBER clinical holds: Center for Biologics Evaluation & Research will hold a meeting of the clinical hold review committee in February. FDA invites biological product companies to submit to the committee the name and number of any investigational biological product trial placed on clinical hold during the past 12 months that the company wants reviewed. Review requests should be submitted to FDA Chief Mediator and Ombudsman Amanda Pederson by Jan. 30, according to a Jan. 11 Federal Register notice...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth